EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+11.44%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.81B
AUM Growth
+$194M
(+12%)
Cap. Flow
+$44.6M
Cap. Flow
% of AUM
2.46%
Top 10 Holdings %
Top 10 Hldgs %
63.7%
Holding
392
New
24
Increased
176
Reduced
102
Closed
74
Top Buys
| 1 |
Futu Holdings
FUTU
|
$31.5M |
| 2 |
Applied Materials
AMAT
|
$29.1M |
| 3 |
Apple
AAPL
|
$15.5M |
| 4 |
Microsoft
MSFT
|
$12.6M |
| 5 |
NVIDIA
NVDA
|
$11.6M |
Top Sells
| 1 |
Advanced Micro Devices
AMD
|
$28.5M |
| 2 |
TSMC
TSM
|
$15.1M |
| 3 |
KE Holdings
BEKE
|
$11.9M |
| 4 |
ASE Group
ASX
|
$7.99M |
| 5 |
Yum China
YUMC
|
$5.17M |
Sector Composition
| 1 | Consumer Discretionary | 39.73% |
| 2 | Technology | 31.74% |
| 3 | Communication Services | 9.52% |
| 4 | Healthcare | 5.08% |
| 5 | Financials | 4.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Ironwood Pharmaceuticals
IRWD
$188M
| $152K | 0.01% |
23,342
-24,755
| -51% | -$161K |
|
302
Arcutis Biotherapeutics
ARQT
$2.06B
| $147K | 0.01% |
15,759
-23,107
| -59% | -$215K |
|
303
Sana Biotechnology
SANA
$752M
| $113K | 0.01% |
20,675
-2,686
| -11% | -$14.7K |
|
304
MannKind Corp
MNKD
$1.7B
| $111K | 0.01% |
21,279
-13,317
| -38% | -$69.5K |
|
305
Cogent Biosciences
COGT
$1.82B
| $94.2K | 0.01% |
11,173
-22,135
| -66% | -$187K |
|
306
Travere Therapeutics
TVTX
$1.93B
| $91K | 0.01% |
11,071
-17,057
| -61% | -$140K |
|
307
Altimmune
ALT
$334M
| $89.5K | ﹤0.01% |
13,458
-28,251
| -68% | -$188K |
|
|
CDMO
308
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $79.9K | ﹤0.01% |
11,194
-13,643
| -55% | -$97.4K |
|
309
Summit Therapeutics
SMMT
$19.3B
| $78.6K | ﹤0.01% |
10,076
-20,653
| -67% | -$161K |
|
310
Relay Therapeutics
RLAY
$710M
| $76.8K | ﹤0.01% |
11,778
-10,152
| -46% | -$66.2K |
|
311
Ocugen
OCGN
$322M
| $75K | ﹤0.01% |
+48,412
| New | +$75K |
|
312
Editas Medicine
EDIT
$248M
| $60.9K | ﹤0.01% |
13,051
-25,031
| -66% | -$117K |
|
313
Scilex Holding
SCLX
$159M
| $60.7K | ﹤0.01% |
898
| – | – |
|
314
Allogene Therapeutics
ALLO
$255M
| $59K | ﹤0.01% |
25,333
-11,797
| -32% | -$27.5K |
|
315
Anavex Life Sciences
AVXL
$807M
| $57.5K | ﹤0.01% |
13,623
-18,036
| -57% | -$76.1K |
|
316
Heron Therapeutics
HRTX
$201M
| $54.7K | ﹤0.01% |
+15,642
| New | +$54.7K |
|
317
C4 Therapeutics
CCCC
$194M
| $52.1K | ﹤0.01% |
11,280
-28,116
| -71% | -$130K |
|
318
Zentalis Pharmaceuticals
ZNTL
$126M
| $41.6K | ﹤0.01% |
10,177
-3,906
| -28% | -$16K |
|
319
Akero Therapeutics
AKRO
$3.58B
| – | – |
-13,899
| Closed | -$351K |
|
320
Alector
ALEC
$305M
| – | – |
-13,025
| Closed | -$78.4K |
|
321
Align Technology
ALGN
$10.1B
| – | – |
-684
| Closed | -$224K |
|
322
Apogee Therapeutics
APGE
$2.26B
| – | – |
-3,125
| Closed | -$208K |
|
323
Arcturus Therapeutics
ARCT
$485M
| – | – |
-7,400
| Closed | -$250K |
|
324
AutoZone
AZO
$70.6B
| – | – |
-255
| Closed | -$804K |
|
325
Baxter International
BAX
$12.5B
| – | – |
-4,788
| Closed | -$205K |
|